RT Journal Article
SR Electronic
T1 Multimodal Molecular Imaging of Integrin α<sub>v</sub>β<sub>3</sub> for In Vivo Detection of Pancreatic Cancer
JF Journal of Nuclear Medicine
JO J Nucl Med
FD Society of Nuclear Medicine
SP 446
OP 451
DO 10.2967/jnumed.113.129619
VO 55
IS 3
A1 Trajkovic-Arsic, Marija
A1 Mohajerani, Pouyan
A1 Sarantopoulos, Athanasios
A1 Kalideris, Evdokia
A1 Steiger, Katja
A1 Esposito, Irene
A1 Ma, Xiaopeng
A1 Themelis, George
A1 Burton, Neal
A1 Michalski, Christoph W.
A1 Kleeff, Jörg
A1 Stangl, Stefan
A1 Beer, Ambros J.
A1 Pohle, Karolin
A1 Wester, Hans-Jürgen
A1 Schmid, Roland M.
A1 Braren, Rickmer
A1 Ntziachristos, Vasilis
A1 Siveke, Jens T.
YR 2014
UL http://jnm.snmjournals.org/content/55/3/446.abstract
AB Pancreatic ductal adenocarcinoma (PDAC) is a lethal disease. Late detection of then nonresectable or metastasized tumors emphasizes the need for novel imaging approaches. Here, we report on so far nonexploited potentials of αvβ3 integrin–targeted molecular imaging technologies for detection of PDAC using genetically engineered mouse models. Methods: Immunohistochemistry and Western blot were used for characterization of αvβ3 expression in murine and human PDAC. We applied IntegriSense 680 fluorescence molecular tomography, intraoperative fluorescence imaging, and 68Ga-NODAGA-RGD PET for αvβ3 integrin molecular in vivo imaging of spontaneous PDAC occurring in Ptf1a+/Cre;Kras+/LSL-G12D;p53LoxP/LoxP mice. (NODAGA is 1,4,7-triazacyclononane-1,4-bis[acetic acid]-7-[2-glutaric acid] and RGD is arginine-glycine-aspartic acid.) Results: αvβ3 integrin is expressed in tumor cells of human and murine PDAC. IntegriSense fluorescence molecular tomography and 68Ga-NODAGA-RGD PET enabled faithful visualization of PDAC. Furthermore, intraoperative optical imaging with IntegriSense 680 allowed good delineation of tumor borders. Conclusion: Imaging approaches targeting αvβ3 integrin expand the potential of molecular imaging for identification of αvβ3-positive PDAC with potential implications in early detection, fluorescence-guided surgery, and therapy monitoring.